Gland Pharma Limited (NSE:GLAND)
India · Delayed Price · Currency is INR 1,958.00
+17.70 (0.91%)
Oct 8, 2025, 3:30 PM IST
Gland Pharma Revenue
Gland Pharma had revenue of 15.06B INR in the quarter ending June 30, 2025, with 7.41% growth. This brings the company's revenue in the last twelve months to 57.20B, down -2.34% year-over-year. In the fiscal year ending March 31, 2025, Gland Pharma had annual revenue of 56.17B, down -0.85%.
Revenue (ttm)
57.20B
Revenue Growth
-2.34%
P/S Ratio
5.64
Revenue / Employee
13.15M
Employees
4,351
Market Cap
322.43B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 56.17B | -482.18M | -0.85% |
| Mar 31, 2024 | 56.65B | 20.40B | 56.29% |
| Mar 31, 2023 | 36.25B | -7.76B | -17.64% |
| Mar 31, 2022 | 44.01B | 9.38B | 27.08% |
| Mar 31, 2021 | 34.63B | 8.30B | 31.51% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 537.77B |
| Divi's Laboratories | 96.52B |
| Cipla | 274.80B |
| Apollo Hospitals Enterprise | 225.51B |
| Mankind Pharma | 129.10B |
| Zydus Lifesciences | 236.08B |
| Fortis Healthcare | 80.94B |
| Alkem Laboratories | 133.04B |
Gland Pharma News
- 12 days ago - These Indian pharma stocks tumble as Trump announces 100% tariff on branded drugs - Business Upturn
- 12 days ago - Gland Pharma shares fall over 4% as Trump announces 100% tariff on pharma imports - Business Upturn
- 12 days ago - Gland Pharma down 4%, Sun Pharma slips 2.6%, Dr Reddy’s down 2%, Zydus nearly 3%, Aurobindo down 2% as Trump’s 100% pharma tariff jolts sector - Business Upturn
- 6 weeks ago - Gland Pharma gets USFDA nod for Vasopressin in 5% Dextrose RTU Injection - Business Upturn
- 2 months ago - Gland Pharma gets USFDA approval for Cangrelor injection with 180-day exclusivity - Business Upturn
- 2 months ago - Gland Pharma shares jump 4% as Q1 revenue rises 7% YoY to Rs 1,505.6 crore, net profit up 50% YoY - Business Upturn
- 2 months ago - Top stocks to watch today, August 6: Bharti Airtel, Lupin, Britannia, NCC, Gland Pharma and more - Business Upturn
- 2 months ago - Gland Pharma share: Jefferies upgrades to hold, Goldman Sachs maintains sell; divergent views on recovery and upside - Business Upturn